可溶性BCMA与非T细胞因素对多发性骨髓瘤BCMA靶向T细胞衔接器难治性的影响
该研究利用全基因组测序和体外实验探讨可溶性BCMA(sBCMA)对BCMA靶向治疗原发难治性的预测作用,并在163例接受teclistamab治疗的患者中验证基线sBCMA>400 ng/mL与难治性相关;增加TCE剂量、使用替代靶点TCE或γ分泌酶抑制剂可克服高sBCMA水平。
要点
- sBCMA可独立预测抗BCMA治疗的原发难治性。
- 肿瘤负荷和表面BCMA抗原密度共同影响抗BCMA TCE的细胞毒效力。
- 163例teclistamab治疗患者验证基线sBCMA>400 ng/mL与难治性相关。
核心结论
- sBCMA可能独立预测抗BCMA治疗的原发难治性。
- 肿瘤负荷和表面BCMA抗原密度共同影响抗BCMA TCE的细胞毒效力。
- 基线sBCMA>400 ng/mL与teclistamab难治性相关。
研究设计与样本
- 利用全基因组测序和体外实验进行研究。
- 对163例接受抗BCMA TCE teclistamab治疗的患者进行相关性分析。
主要发现
- sBCMA可能独立预测抗BCMA治疗的原发难治性。
- 肿瘤负荷和表面BCMA抗原密度共同影响抗BCMA TCE的细胞毒效力。
- 163例teclistamab治疗患者中,基线sBCMA>400 ng/mL与难治性相关。
- 增加TCE剂量、使用针对替代靶点(如GPRC5D)的TCE以及γ分泌酶抑制剂能够克服高sBCMA水平。
关键数值与推荐
- 基线sBCMA>400 ng/mL与teclistamab难治性相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adoptive T-cell therapy is a promising therapy for multiple myeloma (MM), but its efficacy hinges on understanding the relevant biologic and predictive markers of response. B-cell maturation antigen (BCMA) is a key target antigen in MM with active development of multiple anti-BCMA T-cell engagers (TCEs) and chimeric antigen receptor T-cell therapies. The regulation of surface BCMA expression by MM cells, which leads to shedding of soluble BCMA (sBCMA), has triggered debate about the significance of sBCMA as a predictive marker and its potential impact on treatment outcomes. To address this, we leveraged whole-genome sequencing and in vitro assays to demonstrate that sBCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influenced the anti-BCMA TCE cytotoxic efficacy. Correlative analyses of 163 patients treated with the anti-BCMA TCE teclistamab validated and further underscored the association between elevated baseline sBCMA (>400 ng/mL) and refractoriness. Importantly, increasing the TCE dose, using TCE against alternative targets (eg, GPRC5D), and gamma secretase inhibitors were able to overcome the high sBCMA levels. These findings highlight the importance of taking into account the baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, thereby offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.
引用
- Lee H, Durante M, Skerget S, et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 2024. PMID: 39321344. doi:10.1182/blood.2024026212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。